Last reviewed · How we verify

Rifapentine daily for 6 weeks

Centers for Disease Control and Prevention · Phase 2 active Small molecule

Rifapentine daily for 6 weeks is a Small molecule drug developed by Centers for Disease Control and Prevention. It is currently in Phase 2 development. Also known as: priftin.

At a glance

Generic nameRifapentine daily for 6 weeks
Also known aspriftin
SponsorCenters for Disease Control and Prevention
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rifapentine daily for 6 weeks

What is Rifapentine daily for 6 weeks?

Rifapentine daily for 6 weeks is a Small molecule drug developed by Centers for Disease Control and Prevention.

Who makes Rifapentine daily for 6 weeks?

Rifapentine daily for 6 weeks is developed by Centers for Disease Control and Prevention (see full Centers for Disease Control and Prevention pipeline at /company/centers-for-disease-control-and-prevention).

Is Rifapentine daily for 6 weeks also known as anything else?

Rifapentine daily for 6 weeks is also known as priftin.

What development phase is Rifapentine daily for 6 weeks in?

Rifapentine daily for 6 weeks is in Phase 2.

Related